Stock Analiz

Zevra Therapeutics, Inc. ZVRA

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$9.08Market cap $540M
Open the interactive analysis →

Zevra Therapeutics, Inc. (ZVRA) is a healthcare company listed in the US with a market value of about $540M. In the twelve months to September 30, 2026 it had revenue of $148M and net income of $75M, a net margin of 50.7%.

Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 7.4, a price to free cash flow of 14.1, 5-year revenue growth of 52% a year, a 5-year average ROIC of -39%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 24% below the current price.

About Zevra Therapeutics

Zevra Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $13M in 2019 to $106M in 2025, growth of about 42.3% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 66% over three years (dilution for shareholders). It spends 12% of revenue on research and development.

Score: 2.6 / 5

Value3/5
Future growth4/5
Track record2/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • Interest covered more than 5 times
  • Pays a dividend

Valuation

P/E (TTM)7.4
Forward P/E10.2
P/FCF14.1
P/S3.7
P/B2.3
EV/EBITDA3.8
PEG—
Dividend yield0.00%
FCF yield7.1%
Shareholder yield0.0%
Intrinsic value vs. price−24%

Growth and quality

Revenue growth (1 yr)350.9%
Revenue growth (5 yrs, per year)51.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-165.9%
ROIC (5-yr avg.)-38.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$148M$106M$24M$27M$10M$29M$13M$13M$0——
Net income$75M$83M-$106M-$46M-$27M-$9M-$13M-$25M-$56M-$43M-$17M
Free cash flow$38M-$2M-$70M-$34M-$19M$10M-$2M-$24M-$54M-$33M-$30M
EPS (diluted)$1.22$1.35$-2.28$-1.30$-0.78$-2.11$-3.21$-13.23$-50.40$-47.36$-18.08
Net margin50.7%78.2%-446.8%-167.7%-263.5%-29.9%-96.0%-191.0%———
ROIC—-27.7%-68.8%-47.0%-55.6%5.9%-177.0%-400.6%-375.1%-94.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $23.00, 153% above the current price; targets range from $18.00 to $35.00; the consensus rating is “Strong buy”; expected EPS is $1.12 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Zevra Therapeutics’s P/E ratio?

About 7.4, based on the last twelve months of diluted earnings per share (forward P/E about 10.2).

Is Zevra Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 24% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Zevra Therapeutics pay a dividend?

Not currently.

Is Zevra Therapeutics a good stock to buy?

We do not give buy or sell advice. Zevra Therapeutics scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.